NasdaqCM - Nasdaq Real Time Price USD

Assertio Holdings, Inc. (ASRT)

Compare

0.6294

+0.0076

+(1.22%)

At close: 4:00:02 PM EDT

0.6544

+0.03

+(3.97%)

After hours: 5:25:04 PM EDT

iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025

RALEIGH, NC / ACCESS Newswire / March 21, 2025 /iAccess Alpha's Virtual Best Ideas Spring Investment Conference will take place on March 25-26, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and ...

ACCESS Newswire 25 days ago

ACCS

BCHT

IDN
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O’Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025. The Company will present at 1:30 pm Eastern Time on Tuesday, March 25, 2025. To join the presentation, please visit the webcast available online at https://investor.assertiotx.com/. Additionally, in

GlobeNewswire 26 days ago

ASRT
+1.22%
Assertio Holdings Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Assertio Holdings ( NASDAQ:ASRT ) Full Year 2024 Results Key Financial Results Revenue: US$125.0m (down 18% from FY...

Simply Wall St. last month

ASRT
+1.22%
Q4 2024 Assertio Holdings Inc Earnings Call

Q4 2024 Assertio Holdings Inc Earnings Call

Thomson Reuters StreetEvents last month

ASRT
+1.22%
Assertio Holdings Inc (ASRT) Q4 2024 Earnings Call Highlights: Strategic Growth Amidst Challenges

Assertio Holdings Inc (ASRT) reports strong Rovedon sales and strategic leadership additions, while navigating legal and competitive pressures.

GuruFocus.com last month

ASRT
+1.22%
Assertio: Q4 Earnings Snapshot

LAKE FOREST, Ill. AP) — Assertio Holdings, Inc. ASRT) on Wednesday reported a loss of $10.5 million in its fourth quarter.

Associated Press Finance last month

ASRT
+1.22%
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. Said Bre

GlobeNewswire last month

ASRT
+1.22%
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, pl

GlobeNewswire last month

ASRT
+1.22%
Investors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 87% over the last five years

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...

Simply Wall St. 2 months ago

ASRT
+1.22%
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective December 23, 2024, the Compensation Committee of the Company’s Board of Directors granted Mary Pietryga, the Company’s newly-hired Senior Vice President, Chief Commercial Officer, 62,500 restricted stock units (“RSUs”) and 275,000 stock o

GlobeNewswire 3 months ago

ASRT
+1.22%
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company’s Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. “Mark is a highly accomplished commercial leader in complex, competitive t

GlobeNewswire 3 months ago

ASRT
+1.22%
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

Same-day dosing results comparable to next day dosing schedulesLAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cance

GlobeNewswire 3 months ago

ASRT
+1.22%
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

CTO Role to Focus on Growth from New Market and Revenue StrategiesLAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company’s Ch

GlobeNewswire 4 months ago

ASRT
+1.22%
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operatin

GlobeNewswire 4 months ago

ASRT
+1.22%
BEAM
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations

Assertio Holdings ( NASDAQ:ASRT ) Third Quarter 2024 Results Key Financial Results Revenue: US$29.2m (down 18% from 3Q...

Simply Wall St. 4 months ago

ASRT
+1.22%
Q3 2024 Assertio Holdings Inc Earnings Call

Q3 2024 Assertio Holdings Inc Earnings Call

Thomson Reuters StreetEvents 4 months ago

ASRT
+1.22%
Assertio: Q3 Earnings Snapshot

LAKE FOREST, Ill. AP) — Assertio Holdings, Inc. ASRT) on Monday reported a loss of $2.9 million in its third quarter.

Associated Press Finance 5 months ago

ASRT
+1.22%
Assertio Reports Third Quarter 2024 Financial Results

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024. “Third quarter results reflected s

GlobeNewswire 5 months ago

ASRT
+1.22%
Assertio Provides Response to Letter from Short-seller

Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today issued the following let

GlobeNewswire 5 months ago

ASRT
+1.22%
Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024

LAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release third quarter 2024 financial results on Monday, November 11, 2024, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30

GlobeNewswire 5 months ago

ASRT
+1.22%

Performance Overview

Return	ASRT	S&P 500 (^GSPC)
YTD	-27.66%	-8.25%
1-Year	-22.30%	+6.61%
3-Year	-78.66%	+22.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Assertio Holdings, Inc. (ASRT)

iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025

Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

Assertio Holdings Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Q4 2024 Assertio Holdings Inc Earnings Call

Assertio Holdings Inc (ASRT) Q4 2024 Earnings Call Highlights: Strategic Growth Amidst Challenges

Assertio: Q4 Earnings Snapshot

Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

Investors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 87% over the last five years

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations

Q3 2024 Assertio Holdings Inc Earnings Call

Assertio: Q3 Earnings Snapshot

Assertio Reports Third Quarter 2024 Financial Results

Assertio Provides Response to Letter from Short-seller

Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024

Performance Overview